Appropriateness of Ticagrelor Use at Initiation: A Population-Based Cohort Study

Purpose. Ticagrelor is recommended following an acute coronary syndrome if used appropriately. Its use has not yet been well described in the context of ambulatory clinical practice. The objective of this study was to assess the proportion of ticagrelor new users who initiated this medication approp...

Full description

Saved in:
Bibliographic Details
Main Authors: Jean-Pierre Gregoire (Author), Paul Poirier (Author), Norma Pérez (Author), Éric Demers (Author), Jocelyne Moisan (Author)
Format: Book
Published: Frontiers Media S.A., 2018-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_f914a94c6036447f91b16f0f9fc225a1
042 |a dc 
100 1 0 |a Jean-Pierre Gregoire  |e author 
700 1 0 |a Paul Poirier  |e author 
700 1 0 |a Norma Pérez  |e author 
700 1 0 |a Éric Demers  |e author 
700 1 0 |a Jocelyne Moisan  |e author 
245 0 0 |a Appropriateness of Ticagrelor Use at Initiation: A Population-Based Cohort Study 
260 |b Frontiers Media S.A.,   |c 2018-12-01T00:00:00Z. 
500 |a 10.18433/jpps29913 
500 |a 1482-1826 
520 |a Purpose. Ticagrelor is recommended following an acute coronary syndrome if used appropriately. Its use has not yet been well described in the context of ambulatory clinical practice. The objective of this study was to assess the proportion of ticagrelor new users who initiated this medication appropriately and explore associated factors. Methods. A retrospective population-based inception cohort study was conducted using Quebec administrative databases. The study population included all Quebec residents aged ≥18 years who had a first ticagrelor prescription claim between 1 January, 2012, and 31 March, 2015, and had been continuously eligible in the Quebec public drug plan during the 365 days preceding the first ticagrelor claim. The initial ticagrelor prescription was considered appropriate if:1) it met the indication for use criterion, 2) the prescribed daily dose was 90 mg twice a day, and 3) there was a concomitant use of acetylsalicylic acid (ASA) 80-81 mg daily. Factors potentially associated with the ticagrelor appropriateness of use were included in a logistic log-binomial regression model. Results. A total of 7,073 patients were included in the study, 6,013 (85.0%) had an appropriate indication, 6,895 (97.5%) were prescribed ticagrelor 90 mg twice a day, and 6,385 (90.3%) had a concomitant prescription of ASA. A total of 5,371 (75.9%) patients were prescribed ticagrelor in accordance with all criteria. Twelve factors were associated with prescription appropriateness. Conclusions. A large majority of patients initiated ticagrelor appropriately. Further improvement in appropriateness may come at targeting indication for use. 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Journal of Pharmacy & Pharmaceutical Sciences, Vol 22, Iss 1 (2018) 
787 0 |n https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/29913 
787 0 |n https://doaj.org/toc/1482-1826 
856 4 1 |u https://doaj.org/article/f914a94c6036447f91b16f0f9fc225a1  |z Connect to this object online.